Reaction
Minimal Residual Disease reporting signals
As of the last recalculation, Minimal Residual Disease appears in 463 FAERS reports alongside 20 co-occurring drug terms. The strongest observed disproportionality signal is BLINATUMOMAB (PRR 542.3).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Blinatumomab | 99 | 542.3 | 547.5 |
| Azacitidine For | 51 | 141.5 | 141.9 |
| Venetoclax | 108 | 102.5 | 102.7 |
| Azacitidine | 58 | 100.3 | 100.5 |
| Fludarabine Phosphate | 50 | 64.0 | 64.0 |
| Cytarabine | 51 | 42.8 | 42.8 |
| Carfilzomib | 23 | 38.4 | 38.4 |
| Imatinib | 14 | 36.8 | 36.8 |
| Mercaptopurine | 13 | 34.6 | 34.7 |
| Leucovorin Calcium | 14 | 33.9 | 33.9 |
| Dasatinib | 26 | 33.3 | 33.3 |
| Thiotepa | 6 | 28.6 | 28.6 |
| Melphalan | 14 | 28.5 | 28.5 |
| Melphalan Hydrochloride | 15 | 27.8 | 27.8 |
| Etoposide | 40 | 26.7 | 26.7 |
| Obinutuzumab | 9 | 25.1 | 25.1 |
| Busulfan | 8 | 23.2 | 23.3 |
| Pegaspargase | 6 | 22.3 | 22.3 |
| Daratumumab | 17 | 19.8 | 19.8 |
| Acalabrutinib | 4 | 15.0 | 15.0 |